Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of ENC0653 Ointment in Healthy Adults
NCT07684196Phase 1Recruiting
- Sponsor
- EnnovaBio
- Start
- Jun 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ENC0653 (8 arms), sponsored by EnnovaBio. Primary endpoint: Number and types of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) at Day 11. Started Jun 2026; status: recruiting.
02
Drugs
ENC0653
Beyond the preview
Go deeper on NCT07684196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07684196.